Bioequivalence of Shinil Cefadroxil Capsule to Duricef Capsule (cefadroxil 500 mg)

듀리세프 캅셀(세파드록실 500 mg)에 대한 신일 세파드록실 캅셀의 생물학적 동등성

  • Published : 2002.12.01

Abstract

A bioequivalence study of Shin II Cefadroxil capsule (Shin II Pharm. Co. Ltd.) to Duricef capsule(Bo Ryung Pharm. Co. Ltd.), each containing 500 mg of cefadroxil, was conducted. Twenty three healthy Korean male subjects administered each formulation at the dose of 1 capsule (500 mg as cefadroxil) in 2 $\times$ 2 cross-over study. There was a I-week washout period between the doses. Plasma concentrations of cefadroxil were monitored for a period of 8 hr after each administration by an LC/UV method. Area under the plasma concentration-time curve up to 8 hr ($AUC_t$) was calculated by a linear trapezoidal method. $C_{max}$ was compiled from the plasma drug concentration-time data. ANOVA test was conducted for logarithmically transformed $AUC_t$ and $C_{max}$ The results showed that there are no significant differences in $AUC_t$ and $C_{max}$ between the two formulations: The differences between d1e formulations in these log transformed parameters were all for less than 20% (i.e., -0.57%, 3.84% for $AUC_t$ and $C_{max}$, respectively). The 90% confidence intervals for the log transformed data were within the acceptance range of log 0.8 to log 1.25 (i.e., log 0.94~log 1.04 and log 0.95~log 1.10 for $AUC_t$ and $C_{max}$, respectively). Based on d1e bioequivalence criteria of KFDA guidelines, the two formulations of cefadroxil were concluded to be bioequivalent.

Keywords

References

  1. Barbhaiya, R.H., A pharmacokinetic comparison of cefadroxil and cephalexin after administmtion of 250, 500 and l000mg solution doses, Biopharm. Drus Disp., 17, 319-330(1996) https://doi.org/10.1002/(SICI)1099-081X(199605)17:4<319::AID-BDD957>3.0.CO;2-W
  2. Cho H.Y., Lee S., Moon J.D. and Lee Y.B, Biocquivalence of Hanacef Capsule to Duricef Capsulc (Ccfadroxil 500mg), J. Kor. Pharm. Sci., 32, 135-140 (2002) https://doi.org/10.4333/KPS.2002.32.2.135
  3. Gibaldi, M. (1991) Biopharmaceutics and Clinical Pharmaco. kinetic, 4th Ed., Lca & Febiger, Phiadelphia, USA
  4. Lee Y.J., Kim Y.G., Lee M.G., Chung S.J., Lee M.H. and Shim C.K. (2000). Analysis of bioequivalence study using logtransformed model, Yakhakhoeji, 44(4), 308-314
  5. Lindgren, K. (1987). Dctcrminalion of cefadroxil in serum by high-performancc liquid chromatography with cephradine as intemal standard, J. Chromatogr., 413,347-350 https://doi.org/10.1016/0378-4347(87)80252-9
  6. 식품의약품 안전청 고시 제 2001-57호, 생물학적 동등성 시험기준(2001.9.5)